Signal2026-07-17
ClinicalTrials.gov

[PHASE2] Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Part of

Cancer Immunotherapy And Combination Strategies

Open primary sourceSee the whole picture